Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel

• Published in: Blood advances Vol. 8; no. 4; pp. 1018 - 1029
• Main Authors: Sharma, Deva, Kozanoğlu, Ilknur, Ataga, Kenneth I., Benachi, Alexandra, Büyükkurt, Selim, Lanzkron, Sophie, Ozdogu, Hakan, Pancham, Shivan, Pecker, Lydia H., Robinson, Susan E., Yilmaz Baran, Safak, Howard, Jo
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 27.02.2024; The American Society of Hematology
• Subjects: Acute Chest Syndrome - complications; Acute Chest Syndrome - therapy; Anemia, Sickle Cell - complications; Anemia, Sickle Cell - therapy; Aspirin; Blood Transfusion - methods; Female; Humans; Hydroxyurea - therapeutic use; Pregnancy; Red Cells, Iron, and Erythropoiesis
• DOI: 10.1182/bloodadvances.2023011301
• ISSN: 2473-9529

•This international Delphi panel of 12 multidisciplinary experts explored 7 topics related to SCD management during pregnancy.•Based on consensus reached in several areas, recommendations were formulated to inform clinical care for pregnant patients with SCD. [Display omitted] Data to guide evidence-based management of pregnant people with sickle cell disease (SCD) are limited. This international Delphi panel aimed to identify consensus among multidisciplinary experts for SCD management during pregnancy. The 2-round Delphi process used questionnaires exploring 7 topics (antenatal care, hydroxyurea use, transfusion, prevention of complications, treatment of complications, delivery and follow-up, and bottlenecks and knowledge gaps) developed by a steering committee. Thirteen panelists (hematologists, physiologists, obstetricians, maternal fetal medicine, and transfusion medicine physicians) from the United States, the United Kingdom, Turkey, and France completed the first survey; 12 panelists completed the second round. Anonymized responses were collected and summarized by a contract research organization (Akkodis Belgium). Consensus and strong consensus were predefined as 75% to 90% (9-10 of 12) and >90% (≥11 of 12) of panelists, respectively, agreeing or disagreeing on a response to a predefined clinical scenario or statement. In several areas of SCD management, consensus was achieved: experts recommended performing at least monthly multidisciplinary antenatal follow-up, administering prophylactic aspirin for preeclampsia prevention between gestational weeks 12 and 36, initiating prophylactic transfusion therapy in certain cases, or choosing automated red blood cell exchange over other transfusion methods for patients with iron overload or severe acute chest syndrome. No consensus was reached on several topics including the prophylactic aspirin dose, indications for starting infection prophylaxis, routine use of prophylactic transfusions, or use of prophylactic transfusions for preventing fetal complications. These recommendations could inform clinical care for patients with SCD who are pregnant in the absence of large clinical trials involving this population; the identified knowledge gaps can orient future research.